Allakos Inc. 37Z.F Stock
Allakos Inc. Price Chart
Allakos Inc. 37Z.F Financial and Trading Overview
| Allakos Inc. stock price | 1.24 EUR |
| Previous Close | 4.47 EUR |
| Open | 4.33 EUR |
| Bid | 4.34 EUR x 500000 |
| Ask | 4.44 EUR x 500000 |
| Day's Range | 4.33 - 4.33 EUR |
| 52 Week Range | 2.46 - 8.08 EUR |
| Volume | 750 EUR |
| Avg. Volume | 13 EUR |
| Market Cap | 374.55M EUR |
| Beta (5Y Monthly) | 0.42735 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.27 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 143.1 EUR |
37Z.F Valuation Measures
| Enterprise Value | 177.87M EUR |
| Trailing P/E | N/A |
| Forward P/E | -0.85009825 |
| PEG Ratio (5 yr expected) | 2.05 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.3354939 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.076 |
Trading Information
Allakos Inc. Stock Price History
| Beta (5Y Monthly) | 0.42735 |
| 52-Week Change | 85.90% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 8.08 EUR |
| 52 Week Low | 2.46 EUR |
| 50-Day Moving Average | 4.09 EUR |
| 200-Day Moving Average | 5.66 EUR |
37Z.F Share Statistics
| Avg. Volume (3 month) | 13 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 86.56M |
| Float | 51.04M |
| Short Ratio | N/A |
| % Held by Insiders | 4.41% |
| % Held by Institutions | 85.83% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -30.85% |
| Return on Equity (ttm) | -61.19% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -165352000 EUR |
| Net Income Avi to Common (ttm) | -165332992 EUR |
| Diluted EPS (ttm) | -1.86 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 252.6M EUR |
| Total Cash Per Share (mrq) | 2.92 EUR |
| Total Debt (mrq) | 43.37M EUR |
| Total Debt/Equity (mrq) | 15.46 EUR |
| Current Ratio (mrq) | 9.579 |
| Book Value Per Share (mrq) | 3.24 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -135823008 EUR |
| Levered Free Cash Flow (ttm) | -91337000 EUR |
Profile of Allakos Inc.
| Country | Germany |
| State | CA |
| City | San Carlos |
| Address | 825 Industrial Road |
| ZIP | 94070 |
| Phone | 650 597 5002 |
| Website | https://www.allakos.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 123 |
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. In addition, Allakos Inc. is conducting preclinical studies for AK007, which polarizes tumor-associated myeloid cells and promotes anti-tumor immunity. The company was incorporated in 2012 and is headquartered in San Carlos, California.
Q&A For Allakos Inc. Stock
What is a current 37Z.F stock price?
Allakos Inc. 37Z.F stock price today per share is 1.24 EUR.
How to purchase Allakos Inc. stock?
You can buy 37Z.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Allakos Inc.?
The stock symbol or ticker of Allakos Inc. is 37Z.F.
Which industry does the Allakos Inc. company belong to?
The Allakos Inc. industry is Biotechnology.
How many shares does Allakos Inc. have in circulation?
The max supply of Allakos Inc. shares is 90.01M.
What is Allakos Inc. Price to Earnings Ratio (PE Ratio)?
Allakos Inc. PE Ratio is now.
What was Allakos Inc. earnings per share over the trailing 12 months (TTM)?
Allakos Inc. EPS is -2.27 EUR over the trailing 12 months.
Which sector does the Allakos Inc. company belong to?
The Allakos Inc. sector is Healthcare.